Search - tctmd.com

Displaying 321 - 340 of 393

Sort: Relevancy | Date

Presentation ECHO 2017

Guidelines: Assessment of ASD and PFO and Evaluation of a Cardiac Source of Embolism

Presenter: Michael H. Picard

March 31, 2017

News Daily News

Boston Scientific Adds Two More TAVR Valves With Symetis Purchase

Michael O'Riordan

March 30, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Daily News

Only One Third of US States Require AEDs in Schools

Michael O'Riordan

March 28, 2017

News Daily News

Hospital-Level PCI Volume May Not Have a Strong Influence on Outcomes, UK Study Suggests

Todd Neale

March 27, 2017

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

Todd Neale

March 19, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

Advertisement

Guidelines: Assessment of ASD and PFO and Evaluation of a Cardiac Source of Embolism

Boston Scientific Adds Two More TAVR Valves With Symetis Purchase

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Only One Third of US States Require AEDs in Schools

Hospital-Level PCI Volume May Not Have a Strong Influence on Outcomes, UK Study Suggests

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Live From Washington: ACC 2017, Day Two

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content